跳至主要内容
临床试验/JPRN-jRCT1041200075
JPRN-jRCT1041200075招募中2 期

Randomized phase II study of preceding radiofrequency ablation to atezolizuma plus bevacizumab combination therapy for the patients with unresectable hepatocellular carcinoma

Yamashita Tatsuya0 个研究点目标入组 66 人开始时间: 2020年12月15日最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
66

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 ot applicable(—)
性别
All

入选标准

  • clinically diagnosed as hepatocellular carcinoma; unsuitable for local therapy; previously treated by systemic therapy; Preserved liver function; 20 years or older; ECOG Performance status <=2; preservation of major organ function; written informed consent

排除标准

  • refractory ascites or pleural effusion; unsuitable for RFA, risky varices; double cancer; metastases to central nervous system; severe complication; pregnant or lactating women, or women of childbearing potential; mental disorder; patients who investigator regards as inappropriate for candidate

研究者

发起方
Yamashita Tatsuya

相似试验